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Abstract
Background: Comprehensive genomic sequencing (CGS) has the potential to revolutionize precision medicine for
cancer patients across the globe. However, to date large-scale genomic sequencing of cancer patients has been
limited to Western populations. In order to understand possible ethnic and geographic differences and to explore
the broader application of CGS to other populations, we sequenced a panel of 415 important cancer genes to
characterize clinically actionable genomic driver events in 201 Japanese patients with colorectal cancer (CRC).
Methods: Using next-generation sequencing methods, we examined all exons of 415 known cancer genes in
Japanese CRC patients (n = 201) and evaluated for concordance among independent data obtained from US patients
with CRC (n = 108) and from The Cancer Genome Atlas-CRC whole exome sequencing (WES) database (n = 224).
Mutation data from non-hypermutated Japanese CRC patients were extracted and clustered by gene mutation
patterns. Two different sets of genes from the 415-gene panel were used for clustering: 61 genes with frequent
alteration in CRC and 26 genes that are clinically actionable in CRC.
Results: The 415-gene panel is able to identify all of the critical mutations in tumor samples as well as WES, including
identifying hypermutated tumors. Although the overall mutation spectrum of the Japanese patients is similar to that of
the Western population, we found significant differences in the frequencies of mutations in ERBB2 and BRAF. We show
that the 415-gene panel identifies a number of clinically actionable mutations in KRAS, NRAS, and BRAF that are not
detected by hot-spot testing. We also discovered that 26% of cases have mutations in genes involved in DNA double-
strand break repair pathway. Unsupervised clustering revealed that a panel of 26 genes can be used to classify the
patients into eight different categories, each of which can optimally be treated with a particular combination therapy.
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Conclusions: Use of a panel of 415 genes can reliably identify all of the critical mutations in CRC patients and this
information of CGS can be used to determine the most optimal treatment for patients of all ethnicities.
Keywords: Colorectal cancer, Precision medicine, Ethnicity, Japanese, Comprehensive genomic sequencing, Actionable
driver mutation, Hypermutation
Background
Cancer remains the leading cause of death worldwide
with colorectal cancer (CRC) among the most common
indications, accounting for 700,000 deaths per year [1].
Utilizing next-generation sequencing technology, pro-
jects such as The Cancer Genome Atlas (TCGA) and
others have profiled genomic changes in several cancer
types including CRC [2–9]. The ultimate goal of cancer
genome profiling is to enable precision medicine, the tai-
loring of treatments based on unique genomic changes
of each patient’s individual tumor. For instance, the im-
portance of genomic evaluation of RAS and RAF for ad-
vanced CRC patients has been widely accepted, since it
has been revealed that tumors with RAS or RAF
mutations show resistance to anti-EGFR therapies [10].
Initially, mutations in these genes were found to occur
in “hot-spots” (i.e. KRAS codon 12, 13, or BRAF V600E)
[11–13], however, whole exome sequencing (WES) has
revealed that mutations outside of hot-spots can also
influence therapeutic responses [14, 15]. Yet, WES may
not be practical in the clinical setting due to its high
cost, shallow sequencing depth, and excessive infor-
mation about variants/genes of unknown significance
[16, 17]. Although sequencing studies of CRC have
been reported [4, 18–20], tumors from Asian popula-
tions have not been the subject of comprehensive
evaluation. We now report the results from the ana-
lysis of 201 Japanese CRC patients.
Since all of the reported studies examined the muta-
tional spectrum using WES, and WES is clinically
expensive and time-consuming, we hypothesized that
sequencing a panel of cancer-associated genes would
identify essentially all actionable genomic driver muta-
tions and further determine mutational burden in CRC,
both of which can enable development of personalized
treatment strategies. In the current study, we tested this
hypothesis utilizing a 415-gene panel designed for solid
tumors at a very high depth of coverage (~500×) in
Japanese patients (n = 201 tumors) and evaluated for
concordance among independent data obtained from US
patients with colon cancer (n = 108 tumors) (J-CRC and
US-CRC, respectively) and from the TCGA-CRC WES
database (n = 224 tumors). Here, we report that compre-
hensive genomic sequencing (CGS) with a 415-gene
panel can accurately determine high mutation burden
(somatic mutation rate) and that there are differences in
the frequency of mutations in ERBB2 and BRAF. Hier-
archical clustering of clinical data revealed that a subset
of 26 genes can classify all of the CRC patients into eight
categories, each of which can be effectively treated with
available drugs or drugs in development.
Methods
Patient cohorts and sample inclusion criteria
Japanese cohort
A total of 201 patients diagnosed with stage I–IV CRC
according to AJCC 7th edition [21] who had curative
surgery between 2009 and 2015 at Niigata University
Medical and Dental Hospital or Niigata Cancer Center
Hospital were enrolled (Additional file 1: Table S4).
Patients with familial adenomatous polyposis, inflamma-
tory bowel disease, or synchronous multiple CRCs were
excluded.
US cohort
A total of 108 patients with histologically confirmed
diagnosis of primary colorectal adenocarcinoma (stage
I–IV) between 2014 and 2016 submitted for CGS as part
of routine medical examination were included in this
study. All tumor samples that had > 50% tumor content
after macrodissection, as determined through routine
hematoxylin and eosin (H&E) stain by an independent
pathologist, were included. A full waiver of authorization
under the Health Insurance Portability and Accountabil-
ity Act (HIPAA) was granted to enable retrospective
analyses for samples obtained without prior consent. All
data were de-identified prior to inclusion in this study.
Sequencing library preparation
For Japanese and US patient samples, archival tissue in
the form of formalin-fixed, paraffin embedded (FFPE)
tumor or unstained tissue sections obtained during
routine biopsy and/or resection were used for ana-
lysis. An independent pathologist evaluated tumor
content on H&E stained slides for each study sample
to ensure > 50% tumor content was present. Where
applicable, unstained slides were macro-dissected to
enrich for tumor content and genomic DNA (gDNA)
was extracted using BiOstic FFPE Tissue DNA Isolation
Kit (Mo Bio Laboratories, Inc.). All sample prep, CGS,
and analytics were performed in a CLIA/CAP-accredited
laboratory (KEW Inc; Cambridge, MA, USA).
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Comprehensive genomic sequencing
FFPE gDNA (50–150 ng) was converted into libraries
and enriched for the 415 genes with CANCERPLEX
(KEW Inc.; Cambridge, MA, USA). CANCERPLEX is a
clinically validated 415-gene panel enriched for coding
regions and selected introns of genes with known associ-
ation in cancer. Sequencing was performed on the
Illumina MiSeq and NextSeq platforms with average
500× sequencing depth. Genomic data were then proc-
essed through a proprietary bioinformatics platform and
knowledge base to identify multiple classes of genomic
abnormalities including single nucleotide substitutions
(SNPs), small insertions/deletions (indels), copy number
variations (CNV), and translocations in ALK, RET, and
ROS1. A threshold of 10% allelic fraction was used for
SNPs and indels and thresholds of >2.5-fold (gains) and
0.5-fold (loss) were used. To assess somatic status of
mutations in a tumor-only setting, we employed a filter-
ing strategy similar to one recently published [22] with
minor differences. In short, variants were deprioritized if
they were present in a combination of dbSNP, 1000
Genomes, and ExAC databases (at AF > 1%). Next, allele
frequencies for each mutation were used to fit a model
to determine whether the variant is likely germline het-
erozygous or somatic. Finally, results underwent manual
molecular pathologist review validating somatic versus
possible germline status of a variant. Based on published
and our experience, this approach allows the correct
discrimination between germline and somatic variants in
more than 99% of cases. Mutated burden was deter-
mined by non-synonymous SNPs present in the tumor
that have population frequency of < 1% dbSNP and 1000
Genomes databases.
Downsampling TCGA mutation data
COAD-READ mutation data for the TCGA-CRC sam-
ples (n = 224 samples) were downloaded from the Broad
GDAC Firehose website (https://gdac.broadinstitute.org/).
Similar to the 415-gene panel bioinformatics pipeline,
silent mutations that were not protein altering were re-
moved from the dataset. To compare mutation burden of
the 415-gene panel to TCGA WES data, the dataset of
SNPs was downsampled to the 415 genes in the panel and
the mutation rate determined in the panel was calculated
as mutations/Mb. To produce receiver operating charac-
teristic (ROC) curves, genes were selected randomly to
produce panels of 400, 300, 200, 100, and 50 genes. Muta-
tion burden was calculated using only CGS panel genes
and individual ROC curves were used to evaluate how
well mutation burden predicted hypermutated samples.
This process was repeated 100 times and average ROC
curves were produced at each panel size. In addition, indi-
vidual ROC curves were produced using all genes and
only those genes in KEW’s CANCERPLEX panel.
Mutation signature
Each single nucleotide variant (SNV) was classified in a
matrix of the 96 possible substitutions based on the se-
quence context comprising the nucleotides 5′and 3′ to
the position of the mutation. Mutational signatures were
extracted using non-negative matrix factorization ana-
lysis with the SomaticSignatures R package [23] and
plotted with ggplots R package (http://ggplot2.org/).
This analysis identified complex signatures, different
between hypermutated and non-hypermutated cases.
Deconvolution of the complex profiles in order to iden-
tify components matching to COSMIC mutational signa-
tures was done using deconstruct Sigs R package [24].
Mismatch repair immunohistochemistry (MMR-IHC)
Immunohistochemistry (IHC) staining was performed
on the 40 samples of Japanese CRC with highest muta-
tion rates. Slides were stained for four mismatch repair
(MMR) proteins, MLH1 (clone G168-15), MSH2 (clone
FE11) MSH2 (clone BC/44), and PMS2 (clone A16-4),
and were scored by two pathologists. For US clinical
cases, clinical records were reviewed and results of
MMR studies were recorded when available.
Mutation analysis and visualization
Genomic data for Japanese (n = 201) and US patients
(n = 108) obtained from CGS were mined in OncoPrinter
(www.cbioportal.org). Pathway genes were selected based
on previously published TCGA data [4] that are in-
cluded in the 415-gene panel. For TCGA analyses,
genomic profiles were selected in cBioPortal for mu-
tations and putative copy-number alterations from
GISTIC for which tumor sequence data are available
(n = 224). For each pathway, the number of total
uniquely altered cases was determined. Statistical sig-
nificance was determined by Fisher’s exact two-tail
test with a 95% confidence interval. For dsDNA break
repair pathway analysis, the statistical significance of
Japanese and US datasets was determined as com-
pared to TCGA.
To align mutations with their protein domains, gen-
omic data for Japanese, US, and TCGA datasets were
analyzed in Mutation Mapper (www.cbioportal.org).
Lollipop figures were generated for select genes impli-
cated in colorectal adenocarcinoma. For BRAF and
KRAS, data were further segregated by hypermutation
status (hypermutated versus non-hypermutated).
Gene clustering analysis
Mutation data from non-hypermutated J-CRC patients
(n = 184 tumors) were extracted and clustered by gene
mutation patterns. Two different sets of genes from the
415-gene panel were used for clustering: (1) 61 genes
with frequent alteration in CRC; and (2) 26 genes that
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are clinically actionable in CRC. For this analysis, KRAS
and NRAS were integrated into one gene as a RAS.
The number of common mutated genes related to do-
nors i and j was presented as an element cij of an N ×N
matrix, where N is the number of non-hypermutated
donors. In order to normalize the elements of this N di-
mension symmetric matrix into values ranging from 0 to
1, the original element was replaced by 1 / (cij + 1) that
indicated the level of similarity between donors i and j.
Because of this normalization, donors with more com-
mon mutated genes would more possibly come from a
relatively close group. Consequently, a matrix with the
normalized values between all donors was created. Hier-
archical clustering of the matrix was performed for clas-
sifying donor groups with different mutated-gene
patterns by Euclidean distance and Ward’s clustering.
For the 26-gene set, donors were divided into eight
groups based on the hierarchical clustered dendrogram,
which clearly distinguished donors by the different
mutated-gene patterns. On the other hand, for the 61-
gene set, donors were divided into 17 groups. These
clusterings were performed by software R (https://
www.r-project.org/).
Model selection of clustering
Clustering stability was evaluated by R package clValid
for statistical and biological validation of clustering
results (https://cran.r-project.org/web/packages/clValid/
index.html). This method would produce the results of
four stability measures called APN (average portion of
non-overlap), AD (average distance), ADM (average dis-
tance between means), and FOM (figure of merit). For
each index, a lower value means higher stability. We
attempted clustering stabilities for combinations of
different numbers of clusters obtained by cutting a den-
drogram (2–12 for the 26-gene set and 2–24 for the 61-
gene set) with different distance methods (“Euclidean,”
“maximum,” “manhattan,” “canberra,” and “minkowski”)
and clustering methods (“ward.D,” “ward.D2,” “single,”
“complete,” “average,” “mcquitty,” “median,” and “cen-
troid”). All combinations of these three parameters were
evaluated and the parameters with the lowest values of
each stability index were extracted. Of these, the com-
mon parameter sets with relatively lower values among
the four stability indices were selected. The most appro-
priate cluster number, distance method, and clustering
method were determined from the resulted parameter
settings, taking into account that the number of donors
presented in clusters (>5 donors) would be maximized
as possible and the primary mutated genes would be
clear. The final selected parameter settings were the
Euclidean distance method and ward.D clustering in
both sets and eight clusters for the 26-gene set and 17
clusters for the 61-gene set.
Statistical analysis of clinical information
To estimate associations between mutated-gene patterns
and clinical information such as sex, rectum/colon, and
left/right, a two-tailed Fisher’s exact test was applied in
each cluster. Additionally, in order to explore associa-
tions between mutated-gene patterns and tumor aggres-
siveness, seven clinical variables were dichotomized into
less or more aggressive factors for colon cancer onsets
in the following manner: lymphatic invasion (absence/
presence), vascular invasion (absence/presence), histo-
pathological grade (G1/G2 or G3), size of primary tumor
(T1/T2 or T3/T4), spread to regional lymph node (N0
or N1/N2), distant metastasis (M0 or M1), and tumor
stage (I/II or III/IV). In each cluster, two-tailed Fisher’s
exact test was applied to all clinical categories by com-
paring the distribution in a cluster group to that of all
the donors in the other groups. Note that in the case of
statistical signature for 17 hypermutated donors, two-
tailed Fisher’s exact test was conducted against 184 non-
hypermutated donors as a reference set.
Patients were followed every 1–6 months at outpatient
clinics. Medical records and survival data were obtained
for all 104 Stage IV CRC patients. Among them, 46 pa-
tients received anti-EGFR therapies. Seven out of the 46
patients with surgical resection were excluded and 39
patients were included for the analysis of clinical out-
comes. Tumor assessments at baseline included a com-
puted tomography (CT) scan of the abdomen as well as
of other relevant sites of the disease. Follow-up scans to
assess response were obtained after cycles 1 and 2 and
every two cycles thereafter. Responses were determined
using RECIST 1.0. Six patients who showed progression
disease before the first assessment for RECIST were ex-
cluded and 33 patients were included for waterfall plot
analysis. The best calculated responses on the basis of
measurable lesions were analyzed by waterfall plot.
The follow-up period for progression-free survival was
defined as the interval between the date of diagnosis of
metastatic disease and that of progression disease. Sur-
vival curves were constructed using the Kaplan–Meier
method and differences in survival were evaluated using
the log-rank test. Three out of 39 patients were excluded
for Kaplan–Meier analysis based on the clustering, since
each one of three patients was classified into each differ-
ent subtype alone. All statistical evaluations were per-
formed using the SPSS 22 software package (SPSS Japan
Inc., Tokyo, Japan). All tests were two-sided and a P
value < 0.05 was considered statistically significant.
While conducting the two-tailed Fisher’s exact test as
above, the statistical powers of the tests were also esti-
mated by R package statmod (https://cran.r-project.org/
web/packages/statmod/index.html). Some clinical cat-
egories showing significant differences (p < 0.05) were at
insufficient power levels (power < 0.8). It is known that
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power is related to sample size and, in other words, the
power of tests could be promoted by adjusting the effect
size of samples [25]. Therefore, for these significant but
low-power contingency tables, we made a prediction of
the number of donors that could meet a sufficient power
level under the premise that the hypothetical cross-
tabulations had the same cell percentages as that of 184
non-hypermutated donors. The prediction was per-
formed for sample sizes in the range of 20–500 with in-
crements of ten donors for each step and both P value
and power of Fisher’s exact test were calculated for as-
sumed contingency table at each step. By this means, a
minimum effect non-hypermutated donor number was
obtained and this sample size could become a reference
in future studies. The statistical power calculation and
prediction for the above-mentioned Fisher’s exact test
were simulated 1000 times for each cross-tabulation.
Gene-based statistical analysis
To estimate associations between genes and tumor ag-
gressiveness, we performed Fisher’s exact test for each
gene in seven clinical categories. Subsequently, signifi-
cant genes with at least one clinical category (p < 0.05)
were extracted. A matrix between the genes and the
clinical categories were created based on log odds ratio
for the extracted genes. Finally, the matrix was clustered
by Euclidean distance and Ward’s method. In this clus-
tering, positive and negative infinity values are replaced
by 4 and −4 as pseudonumbers, respectively.
Results
Genomic alterations in cancer signaling pathways
Utilizing the CGS platform (Additional file 1: Table S1),
we assessed the genes and pathways most frequently al-
tered in the test samples (Fig. 1). We found that the
same sets of alterations were generally detected by both
WES and CGS. Genomic alterations in oncogenic path-
ways involving cell cycle, RAS/RAF, PI3K, and WNT
were comparable (Fig. 1) [4]. However, we found statisti-
cally significant differences in ERBB2 (p < 0.05), APC
(p < 0.001), TP53 (p < 0.001), CDKN2A (p < 0.05), and
NRAS (p < 0.05) mutations in Japanese patients as
compared with US patients (Fig. 1a–c), which may
reflect epidemiological differences between the two
populations [26, 27].
Given the recent recognition that tumors with DNA
double-strand break repair defects (most notably
BRCA1/2 mutations) are more sensitive to PARP
inhibitors [28] and the recent approval of olaparib for
advanced ovarian cancer, we undertook a comprehensive
analysis of the DNA double-strand break repair pathway.
Currently BRCA1/2 mutation status alone is used to
identify patients for olaparib treatment; however, muta-
tions in other genes can lead to DNA double-strand
break repair defects [28, 29]. Therefore, those genes may
also be useful in determining olaparib sensitivity. Ex-
cluding TP53, which is not used for selection of PARP
inhibitors, we analyzed the five DNA repair pathway
genes that are most commonly mutated in Japanese and
US patients and compared with TCGA samples (Fig. 1d
and e). We found genomic alterations in all five DNA
repair genes, including BRCA2, which represent a sig-
nificant proportion of CRC patients (26% of Japanese,
21% of US, and 19% of TCGA samples).
Mutation rates detected by targeted sequencing with
cancer gene panel
The clinical significance of identifying hypermutated tu-
mors has recently been demonstrated in several studies
correlating mutation burden with the development of
neo-antigens and clinical response to immunotherapy
drugs [4, 30–33]. We found hypermutated tumors as
identified by CGS: 17 (8%) in J-CRC and two (3%) in
US-CRC (Fig. 2a and b), generally correlated with DNA
mismatch repair deficiency (MMR-D) as detected by
standard clinical IHC evaluation for MMR proteins
(MLH1, MSH2, MSH6, and PMS2). For Lynch syndrome
genes, both somatic and potentially germline pathogenic
mutations were included in the analysis (see “Methods”).
One patient showed loss of MSH2 expression by IHC
supported by genetic loss for MSH2 gene without a
hypermutated phenotype while conversely two patients
with the highest mutation burdens were MMR-intact
and microsatellite stable but had POLE mutations, dem-
onstrating that although often useful in predicting
hypermutation status, neither MMR-D nor MSI-H alone
can fully predict all hypermutated tumors. Similar ana-
lysis of US-CRC clinical cases confirmed the ability of
CGS to detect hypermutated tumors, although the clin-
ical bias to perform CGS on advanced cases of MSS-
CRC in US community oncology practice may explain
the low percentage of hypermutated tumors found in
these samples. To further validate utility of CGS in iden-
tifying hypermutated tumors, we downsampled the
TCGA WES data (n = 224 tumors) [4] to the subset of
415 genes in the CGS platform. This analysis not only
accurately identified the hypermutated tumors (both
MMR-deficient and MMR-intact) but also showed
strong correlation in mutation rates between the 415-
gene panel and WES (Fig. 2c). The average mutation rate
detected by CGS was higher than that detected by WES
reflecting the fact that the panel content was in part
selected to include genes more frequently mutated in
cancer. We further downsampled the TCGA data to ran-
dom gene panels of descending size (400, 300, 200, 100,
and 50) and determined that panels smaller than 300
genes lacked sufficient statistical power to accurately
identify hypermutated cases (Fig. 2d), thus demonstrating
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that the CGS platform (roughly 1/2000th of the genome)
is comparable to WES in generating mutation rates and to
distinguish hypermutated and non-hypermutated tumors.
We further explored the utility of CGS to provide clin-
ically meaningful patterns of mutational signatures [34]
from the J-CRC cohort (Fig. 2e). Based upon the signa-
tures described in COSMIC (http://cancer.sanger.ac.uk/
cosmic)), we found that Signatures 20 and 26 contrib-
uted the largest proportion of total somatic SNVs and
were similar to previous findings. Both signatures were
associated with defective DNA repair [34]. Interestingly,
in the hypermutated-cases only we identified Signature
10 (C > A SNVs at TpCpT context), previously shown to
correlate with altered activity of DNA polymerase epsi-
lon [34] (termed “ultra-hypermutators” by COSMIC). In-
deed, we determined that the two cases with the highest
mutation burdens were MMR-intact with mutations in
their POLE gene: V411L in the exonuclease (proofread-
ing) domain in one case and P286R in the polymerase
domain in the other demonstrating the capacity of CGS
in identifying clinically useful mutational signatures.
Genomic evaluation of key driver genes
Recent updates in clinical guidelines, in both Japan and
in the US, have made the genomic evaluation of KRAS,
NRAS, and BRAF essential for treatment planning. Most
mutations in these genes cluster in “hot-spots” (i.e.
KRAS codon 12, 13; NRAS codon 61; BRAF codon 600);
however, data from large full-gene sequencing projects
have identified additional mutations outside these hot-
spots (e.g. KRAS codon 22, 33, 59, etc.). We compared
the distribution of somatic mutation across these key
genes between Japanese and US cohorts and with the
TCGA (Fig. 2f–h, Additional file 1: Figure S1). While the
KRAS mutation patterns in different cohorts appeared
similar, BRAF mutation patterns presented key differ-
ences. BRAF mutations present in TCGA-CRC samples
were predominantly represented by V600E which is
often restricted to hypermutated tumors and agrees with
previous reports [35–37]. The TCGA database shows
that BRAF mutations in non-hypermutated tumors were
also significantly more frequent in right-sided tumors. In
contrast to previous studies, both Japanese and US-CRC
cases had a wide range of non-V600E mutations inside
and outside the kinase domain including D594G, a
kinase-dead BRAF that can drive tumor progression
through interactions with CRAF [38]. In addition, BRAF
mutations were found in both left-sided and right-sided
tumors (Additional file 1: Table S2). This finding may
suggest unique therapeutic strategies for not only right-
sided, but also left-sided tumors that were enriched for






Fig. 1 Genetic aberrations across common oncogenic pathways in CRC. Japanese patients (a) and US patients (b) were evaluated for gene
alterations in the key cancer pathways. Amplification (red), deletion (blue), missense point mutations (green), or frameshift mutations (brown).
Altered cases are defined as the total number of unique samples with a genetic aberration in each pathway. c Percent of patients with a variation
for each given gene. Statistical significance was determined using Fisher’s exact test. d J-CRC, US-CRC, and TCGA sample data were evaluated for
gene alterations in the dsDNA break repair pathway in the 415-gene panel. e Percent of patients with a variation for each given gene. Statistical
significance was determined using Fisher’s exact test
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findings in TCGA-CRC cases [39], we found APC
and RNF43 truncating mutations mutually exclusive in
J-CRC and in US-CRC (Fig. 1) with significant enrich-
ment of RNF43 alterations, particularly G659 mutations,
in MMR-deficient tumors (Additional file 1: Figure S2).
Analysis of additional key driver genes showed similar
patterns of mutation between Japanese, US, and TCGA
cohorts (Additional file 1: Figure S1). Similar to TCGA
results, no gene fusions were found in well-characterized
driver genes ALK, RET, or ROS1.
Genomic alterations and tumor aggressiveness
Unlike earlier genomic profiling studies, this study also
included clinical outcomes data that was used to deter-
mine the relationship between mutation profile and pa-
tient outcomes. CRC is a clinically diverse disease and it
has been long considered that genomic heterogeneity is
vital to understanding this diversity. Tumors can be clas-
sified by degree of lymphatic invasion, vascular invasion,
histopathological grade, TNM classifications, and tumor




Fig. 2 Mutation rates in Japanese and US CRC patients. Mutation rates from Japanese patients (a) and US patients (b) were determined by
the number of non-synonymous SNVs in the 415-gene panel. Hypermutated and non-hypermutated cancers separated by the dashed line. Red,
MMR-deficient; gray, MMR-intact; white, no data. c Data from TCGA CRC cases (green) were downsampled to the content of the 415-gene CGS platform
(blue; non-synonymous SNPs). Correlation between mutation rates determined by CGS and WES (insert). d ROC analysis using the 415-gene CGS
platform, WES, and random sets of 400, 300, 200, 100, and 50 genes as predictors of hypermutated samples (TCGA dataset). e Aggregated mutational signature
profiles for hypermutated (top) and non-hypermutated cases (bottom). The pie charts represent inferred contribution of COSMIC signatures to corresponding
profiles. f Mutations in BRAF for Japanese patients (n=201), US patients (n= 108), and TCGA samples (n=224) were aligned to protein domains. The number
of mutations at each given amino acid were plotted in corresponding pie graphs. As shown, BRAF V600E was the highest frequency mutations in each protein.
Patient samples were further plotted by mutation status: (g) BRAF-hypermutated, (h) BRAF-non-hypermutated
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between gene alterations and clinical features. Among
the 415 genes, we found that genes significantly enriched
in at least one certain category (p < 0.05) were distinctly
classified into more aggressive or less aggressive groups
(Additional file 1: Figure S3 and Table S3). For example,
mutations in genes such as PTEN, SMAD2, TGFB2, and
SRC implicated in epithelial-mesenchymal transition,
metastasis, and cancer progression [40, 41], were enriched
in more aggressive groups while the other genes clustered
in the less aggressive groups.
Cluster analysis for Japanese CRC mutations
Several approaches to identify genomic subtypes have
been proposed to correlate genomic landscape with clin-
ical features in CRC. Despite differing methods of
classification, the hypermutated subtype has commonly
emerged across various genomic profiling efforts. In
agreement with these findings, we identified a subgroup
of 17 Japanese patients with hypermutated tumors as
characterized by CGS (Fig. 1). We therefore performed
hierarchical clustering of mutations in a subset of genes
frequently altered in CRC (n = 61 genes) in the Japanese
cohort of non-hypermutated patients (n = 184 tumors)
to further assess the association between gene alterations
and clinical features in CRC (Additional file 1: Figure S4).
We identified that all patients can be classified into 12
typical clusters (Additional file 1: Figure S4). We further
examined associations between each of these clusters with
clinicopathological features, such as sex, tumor location,
and pathologic stage (Additional file 1: Figure S4B).
Of note, patients in Cluster 7 (n = 49 tumors) with
primary mutated genes APC and TP53 significantly
associated with the location of left side (p < 0.01), less
lymph node metastasis (p < 0.05), and less distant
metastasis (p < 0.05) compared with patients in all
other clusters (Additional file 1: Figure S4B). These
findings suggest that there are clear associations
between mutation spectrum and clinical characteristics of
Japanese CRC patients.
Additional cluster analysis on a subset of 26 genes as-
sociated with targeted therapies either already approved
or in late-phase development in Japan (Phase II or III)
(Fig. 3, Additional file 1: Figure S5A) identified seven
clusters with mutated genes and a single cluster with no
mutated genes. Patients with KRAS mutations (Clusters
6–8; n = 75 tumors) were classified into three clusters,
while patients without KRAS mutations were classified
into either Cluster 1 (n = 49 tumors) with “all wild-type”
genes or Clusters 2–5 (n = 60 tumors) with mutations in
actionable driver genes including ERBB2, PIK3CA,
RNF43, BRAF, and PTEN. Patients in Cluster 1 were
associated with tumors in the left side (p < 0.01), while
patients in Cluster 7 (n = 17 tumors) with RAS and
PIK3CA mutations were associated with tumors on the
right side (p < 0.05), consistent with previous reports
[42]. Interestingly, patients in Cluster 2 (n = 8 tumors)
with ERBB2 mutations were associated with smallest
tumor size, significantly less lymphatic invasion (p < 0.01)
and early stage (p < 0.05), while patients in Cluster 5
(n = 29 tumors) harboring PTEN mutations exhibited
significantly more lymphatic (p < 0.05) and vascular
invasion (p < 0.01) with more metastasis.
Outcome of Stage IV CRC patients and clinical potential
of cluster analysis based on CGS platform
Next, we examined clinical outcomes of Stage IV CRC
patients to explore the clinical potential of cluster ana-
lysis based on CGS for Japanese CRC patients. Kaplan–
Meier analysis for patients with Stage IV CRC (n = 102,
excluded two hypermutated cases) revealed that overall
survival rates were significantly different among the
subtypes based on cluster analysis on a subset of the
26 genes associated with targeted therapies (Fig. 3,
Additional file 1: Figure S5B). The 26 genes included
RTK and RAS pathway, such as KRAS, BRAF, NRAS,
and ERBB2, which have known associations with
resistance to anti-EGFR targeted therapies in CRC pa-
tients [10]. We therefore hypothesized that the cluster
analysis based on the 26 genes estimates the effect of
anti-EGFR therapies. Waterfall plot analysis demon-
strated the best calculated responses on the basis of
measurable lesions in 33 patients treated with anti-
EGFR therapies and revealed that all the three pa-
tients with progressive disease belong to subgroups
with actionable driver mutations (RNF43 and BRAF;
Cluster 4 and RAS; Cluster 6), but not subgroup of
“all wild-type” without actionable mutations (Cluster 1)
(Fig. 4a). Moreover, in agreement with previous findings
[43], swimmers plot and Kaplan–Meier analysis demon-
strated that patients in subgroup of “all wild-type” showed
significantly better progression-free survival as compared
to patients in subgroups of “mutated” (Clusters 2–6 and
hyper-mutated subgroup) (p = 0.009) (Fig. 4b and c).
Moreover, Kaplan–Meier analysis further demonstrated a
significant difference among subgroups when the sub-
groups with actionable mutations were stratified based
on the clustering (p = 0.001) (Fig. 4d). These findings
indicate clinical potential of clustering based on the
415-gene CGS platform with its ability to estimate
the survival of patients with Stage IV CRC treated
with targeted therapies.
Discussion
In the current study, we performed CGS sequencing
with a 415-gene panel to probe actionable driver muta-
tions at a very high depth of coverage in the largest
series of Japanese patients (n = 201 tumors) and evalu-
ated for concordance among independent data obtained
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from US patients with colon cancer (n = 108 tumors)
and from the TCGA-CRC WES database (n = 224
tumors). We identified overall similarities and some
distinct population differences in detecting clinically ac-
tionable oncogenic driver events. We correlated muta-
tion burden with DNA mismatch repair status, obtained
clear genomic mutational signatures, and identified gen-
omic alteration patterns in Japanese and the US-CRC
patients similar to those previously identified by WES by
the TCGA. We also found statically significant increases
in ERBB2 APC, TP53, and NRAS mutations in Japanese
patients as compared with US patients, which may
reflect epidemiological differences between the two
populations. Interestingly, we found that 11 of 24
BRAF mutations occurred outside the hot-spot
V600E. Since mutations other than V600E are known
to be activating, our results underscore the import-
ance of sequencing all BRAF exons to assess the opti-
mal therapeutic approach. Moreover, we report here a
novel, significant correlation between APC and TP53
mutations with tumors presented on the left side, em-
phasizing the utility of CGS sequencing as an invalu-
able resource for better understanding the genomic
landscape of CRC.
Fig. 3 Cluster of 26-gene co-mutation patterns. Cluster analysis was performed on non-hypermutated Japanese CRC samples (n = 184 tumors) by
using Euclidean distance and Ward’s clustering method and co-mutation patterns of the 26-gene subset with statistical analysis are shown.
Mutation rate in each group is shown as a bar graph in the middle panel. Group-based mean values for age and tumor diameter are shown (left)
with cluster colors and fraction for clinical information (right). Dark bars indicate significant difference (p < 0.05, two-tailed Fisher’s exact test) to the
distribution of all other non-hypermutated donors, light bars are non-significant (*p < 0.05, **p < 0.01). Chemo chemotherapy; Cmab Cetuximab; Pmab
Panitumumab; Bmab Bevacizumab. †Combination therapy with other inhibitors (e.g. anti-EGFR, MEK inhibitors) will be recommended
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To explore the clinical potential of CGS, we performed
cluster analysis with the set of clinically actionable genes
in CRC (n = 26 genes) related to targeted therapies either
approved or in late-phase development in Japan and ob-
tained eight typical subgroups in addition to the “hyper-
mutated” subgroup. CRC patients in the “hypermutated”
subgroup are expected to benefit most from treatment
with immune checkpoint inhibitors. Patients in the “all
wild-type” cluster (Cluster 1) may respond best to anti-
EGFR therapies, such as Cetuximab and Panitumumab
given the lack of contraindicated KRAS mutations.
However, patients in Clusters 2–5 had driver mutations
downstream of the EGFR pathway, suggesting resistance
to anti-EGFR therapies and hence better response to
therapies targeting PIK3CA, ERBB2, RNF43/BRAF, or
PTEN. Patients in Clusters 6–8 had KRAS mutations and
therefore may benefit from chemotherapy + Bevacizumab
given their expected resistance to anti-EGFR therapy.
Thus, these findings underscore the clinical potential of
examining a smaller (26 gene) panel, by which we could
identify suitable targeted therapies based on the cluster-
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Fig. 4 Clinical outcomes of Stage IV patients treated with anti-EGFR therapies. a Waterfall plot for 33 patients with Stage IV CRC after anti-EGFR targeted
therapy in addition to cytotoxic chemotherapy. The vertical axis shows the best calculated responses on the basis of measurable lesions in each individual
patient. b Swimmers plot for 39 patients with Stage IV CRC treated with anti-EGFR therapies. The horizontal axis shows progression-free survival for each
patient. c, d Kaplan–Meier survival estimates according to genomic subgroups. c Progression-free survival was analyzed in 39 patients with Stage IV CRC
treated with anti-EGFR therapies. The patients were divided to “All WT (wild type)” (Cluster 1; n= 15) or “Mutated” (Clusters 2–8; n= 24) based on the cluster
analysis with targeted therapy-related 26 genes. d Progression-free survival was analyzed for 36 patients with Stage IV CRC treated with anti-EGFR therapies
based on subgroups (All WT, cluster 1; RNF and BRAF, cluster 4; PTEN, cluster 5; RAS, cluster 6) by clustering with the 26 genes
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Given the clinical significance of hot-spot KRAS
mutations (codons 12 and 13) in patients with ad-
vanced CRC to anti-EGFR therapy resistance, KRAS
mutation testing has become mandatory testing in
Japanese patients before administering anti-EGFR
therapy [44]. Indeed, most of the patients treated with
anti-EGFR therapies in this study had been identified
not to have hot-spot KRAS mutations (codons 12 and
13) and thus considered as KRAS wild-type, except
for a few patients who had been treated before testing
became required. Recent studies have identified alter-
ations in genes downstream of EGFR (RTKs and RAS
pathway) in addition to hot-spot KRAS mutations as
likely indicators of primary and secondary resistance
to anti-EGFR antibody therapies [10]. We therefore
probed the clinical relevance of gene alterations in
RTKs and RAS pathway in addition to KRAS muta-
tions as identified by CGS in Japanese CRC patients.
Interestingly, there were three patients with progres-
sive disease on anti-EGFR therapy and CGS revealed
that two out of the three patients had previously un-
identified mutations downstream of EGFR emphasizing
that hot-spot testing alone is inadequate in guiding
therapeutic strategies. Moreover, Kaplan–Meier ana-
lysis demonstrated that patients in the subgroup with-
out alterations in RTKs and RAS pathway showed
significantly better progression-free survival than pa-
tients in subgroups with mutations, although most of
the patients had been previously considered as KRAS
wild-type. Taken together, we have demonstrated that
CGS captures broad actionable genomic driver muta-
tions in Japanese patients with advanced CRC satisfy-
ing a currently unmet critical need to better guide
personalized therapeutic approaches in Japan.
Conclusions
We demonstrate concordance of CGS between Japanese
and US patients with CRC and with WES in the TCGA
database. We further illustrate how CGS testing captures
broad actionable genomic driver mutations as well as
high mutational burden and highlight its potential to
impact clinical outcomes of patients. These findings
emphasize the clinical potential of CGS for patients with
CRC in Japan and warrant further clinical investigation
through prospective randomized clinical trials to con-
firm the application.
Additional file
Additional file 1: Figure S1. Location of genetic aberrations for
Japanese and US patients, and TCGA samples. Mutations in (A) APC, (B)
ERBB2, (C) TP53, (D) NRAS, and (E) KRAS for Japanese patients (n = 201),
US patients (n = 108), and TCGA samples (n = 224) were aligned to
protein domains. The number of mutations at each given amino acid
were plotted in corresponding pie graphs. As shown, KRAS G12 were the
highest frequency mutations. Patient samples were further plotted by
mutation status (F) KRAS-hypermutated and (G) KRAS-non-hypermutated.
Figure S2. Correlation of RNF43 mutations with MMR. (A) The frequencies
of APC and RNF43 mutations were determined by MMR phenotype.
Statistical significance was determined by Fisher’s exact test. (B) Mutation
mapper analysis identified G659 as most frequently altered in MMR-D cases.
Figure S3. Gene-based statistical analysis for clinical information. Genes
were filtered based on Fisher’s exact test (p < 0.05). Cell values are log odds
ratios colored from blue to red. Dendrograms were created by Euclidean
distance and Ward’s method. Less (blue) or more (red) aggressive factors of
seven clinical variables are shown: lymphatic invasion (ly), vascular invasion
(v), histopathological grade (G), TNM classifications (T, N, and M), and tumor
stage. Figure S4. Cluster of 61-gene co-mutation patterns. (A) Cluster
analysis was performed on non-hypermutated Japanese CRC samples
(n = 184 tumors) by using Euclidean distance and Ward’s clustering method
(closest distance to common mutated genes are colored yellow to blue). (B)
Co-mutated gene patterns of the 61-gene set with statistical analysis.
Mutation rate in each group is shown as a bar graph in the middle panel.
Group-based mean values for age and tumor diameter are shown (left) with
cluster colors and fraction for clinical information (right). Dark bars indicate
significant difference (p < 0.05, two-tailed Fisher’s exact test) to the
distribution of all other non-hypermutated donors, light bars are
non-significant (**p < 0.01, *p < 0.05). Figure S5. Data complementary
to Fig. 3. (A) Cluster analysis was performed on non-hypermutated
Japanese CRC samples (n = 184 tumors) by using Euclidean distance
and Ward’s clustering method (closest distance to common mutated
genes are colored yellow to blue). (B) Kaplan–Meier survival estimates
according to genomic subgroups. Overall survival was analyzed in
102 patients with Stage IV CRC treated with anti-EGFR therapies. The
patients were divided to “All WT (wild type)” (Cluster 1; n = 25) or
“Mutated” (Clusters 2–8; n = 77) based on the cluster analysis
with targeted therapy-related 26 genes. Table S1. The 415-gene list
for the CGS platform. Table S2. BRAF mutation and tumor location
(J-CRC, n = 201). Table S3. Raw data for gene-based statistical analysis
for clinical information. Table S4. Clinicopathological characteristics
of 201 CRC patients. (PDF 1435 kb)
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